Simeng Lin

19PUBLICATIONS
80CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Nanotoxicology, health and safetyInnate immunityMolecular targetsPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (19)

|Oct 13, 2025
Understanding Anti-TNF Treatment Failure: Pre-Existing Antidrug Antibodies Are Common but Do Not Neutralize Drug Activity In Vitro or Influence Clinical Response to Infliximab or Adalimumab in Patients with Crohn Disease.

Rachel Nice, Simeng Lin, Neil Chanchlani

|Jun 23, 2025
Clinical Utility and Cost-Effectiveness of Pretreatment NUDT15 Pharmacogenetic Testing to Prevent Thiopurine-Induced Myelosuppression: A Genotype-First Reverse Phenotyping Cohort Study Within the UK NIHR Inflammatory Bowel Disease Bioresource.

Christopher Roberts, Jaime Peters, Aleksejs Sazonvos

|Oct 06, 2023
Baseline TREM-1 Whole Blood Gene Expression Does Not Predict Response to Adalimumab Treatment in Patients with Ulcerative Colitis or Crohn's Disease in the SERENE Studies.

Bram Verstockt, Valerie Pivorunas, Naim Al Mahi

|Sep 30, 2023
Baseline Expression of Immune Gene Modules in Blood is Associated With Primary Response to Anti-TNF Therapy in Crohn's Disease Patients.

Benjamin Y H Bai, Mark Reppell, Nizar Smaoui

|Aug 08, 2023
Whole Blood DNA Methylation Changes Are Associated with Anti-TNF Drug Concentration in Patients with Crohn's Disease.

Simeng Lin, Eilis Hannon, Mark Reppell

|Jun 02, 2023
Pretreatment Vitamin D Concentrations Do Not Predict Therapeutic Outcome to Anti-TNF Therapies in Biologic-Naïve Patients With Active Luminal Crohn's Disease.

Neil Chanchlani, Simeng Lin, Rebecca Smith

Pageof 4

Frequent Collaborators

16 joint publications

Neil Chanchlani

16 joint publications

Tariq Ahmad

15 joint publications

James R Goodhand

14 joint publications

Nick Kennedy